Okada Kenjiro, Uemura Kenichiro, Satoi Sohei, Fujii Tsutomu, Kawai Manabu, Yamaki So, Watanabe Toru, Motobayashi Hideki, Takahashi Shinya
Department of Surgery, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan.
Department of Surgery Kansai Medical University Osaka Japan.
Ann Gastroenterol Surg. 2025 Jan 2;9(4):794-803. doi: 10.1002/ags3.12903. eCollection 2025 Jul.
Antimicrobial prophylaxis is routinely administered in patients undergoing distal pancreatectomy, with cephalosporins being the most frequently used agents. However, there is limited evidence regarding optimal duration of antimicrobial prophylaxis. This study aimed to evaluate the optimal duration of antimicrobial prophylaxis in distal pancreatectomy.
A multicenter cohort study was performed using a common database of patients who underwent distal pancreatectomy between April 2017 and March 2022 at four high-volume centers in Japan. Eligible patients were divided into two groups according to the duration of antimicrobial prophylaxis: intraoperative or up to 24 h after surgery and more than 24 h after surgery. Primary endpoint was the incidence of surgical site infections.
A total of 496 patients were enrolled in this study, including 254 and 242 patients categorized into the intraoperative or up to 24-h and more than 24-h groups, respectively. Surgical site infections occurred in 129 patients (26%). The intraoperative or up to 24-h group had a significantly lower incidence of surgical site infection (19% vs. 33%, < 0.001) and infectious clinically relevant postoperative pancreatic fistula (8% vs. 17%, = 0.002). There were no significant differences in severe surgical site infection rates between the groups. Multivariate logistic regression identified more than 24-h administration of antimicrobial prophylaxis as an independent risk factor for surgical site infections ( = 0.001).
Prolonged administration of antimicrobial prophylaxis may not be effective in preventing surgical site infections after distal pancreatectomy compared to intraoperative or up to 24-h administration.
在接受胰体尾切除术的患者中,通常会进行抗菌药物预防,头孢菌素是最常用的药物。然而,关于抗菌药物预防的最佳持续时间的证据有限。本研究旨在评估胰体尾切除术中抗菌药物预防的最佳持续时间。
使用一个共同数据库进行了一项多中心队列研究,该数据库收录了2017年4月至2022年3月期间在日本四个高容量中心接受胰体尾切除术的患者。符合条件的患者根据抗菌药物预防的持续时间分为两组:术中或术后24小时内以及术后超过24小时。主要终点是手术部位感染的发生率。
本研究共纳入496例患者,其中分别有254例和242例患者被归类为术中或术后24小时内组和术后超过24小时组。129例患者(26%)发生了手术部位感染。术中或术后24小时内组的手术部位感染发生率显著较低(19%对33%,<0.001),感染性临床相关术后胰瘘发生率也较低(8%对17%,=0.002)。两组之间严重手术部位感染率无显著差异。多因素逻辑回归分析确定抗菌药物预防超过24小时的使用是手术部位感染的独立危险因素(=0.001)。
与术中或术后24小时内使用相比,延长抗菌药物预防时间可能对预防胰体尾切除术后的手术部位感染无效。